These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 23157628)

  • 1. The role of GABA-A receptor in the synergism between SSRI and antipsychotic in schizophrenia; implications for antipsychotic modes of actions.
    Silver H; Einoch R; Youdim M; Weinreb O
    Curr Med Chem; 2013; 20(3):363-70. PubMed ID: 23157628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?
    Silver H; Chertkow Y; Weinreb O; Danovich L; Youdim M
    Neurotherapeutics; 2009 Jan; 6(1):86-93. PubMed ID: 19110201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients.
    Silver H; Susser E; Danovich L; Bilker W; Youdim M; Goldin V; Weinreb O
    Int J Neuropsychopharmacol; 2011 Jun; 14(5):573-84. PubMed ID: 21208484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment.
    Danovich L; Weinreb O; Youdim MB; Silver H
    Int J Neuropsychopharmacol; 2011 Mar; 14(2):143-55. PubMed ID: 20181299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia.
    Einoch R; Weinreb O; Mandiuk N; Youdim MBH; Bilker W; Silver H
    Eur Neuropsychopharmacol; 2017 May; 27(5):470-483. PubMed ID: 28410959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.
    Chertkow Y; Weinreb O; Youdim MB; Silver H
    J Neural Transm (Vienna); 2009 Nov; 116(11):1529-41. PubMed ID: 19578925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex.
    Danovich L; Weinreb O; Youdim MB; Silver H
    Psychopharmacology (Berl); 2012 Apr; 220(4):763-70. PubMed ID: 21989809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The place of SSRIs in the treatment of schizophrenia].
    Zullino D; Delacrausaz P; Baumann P
    Encephale; 2002; 28(5 Pt 1):433-8. PubMed ID: 12386545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in verbal memory following SSRI augmentation of antipsychotic treatment is associated with changes in the expression of mRNA encoding for the GABA-A receptor and BDNF in PMC of schizophrenic patients.
    Silver H; Mandiuk N; Einoch R; Susser E; Danovich L; Bilker W; Youdim M; Weinreb O
    Int Clin Psychopharmacol; 2015 May; 30(3):158-66. PubMed ID: 25756551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Expert Opin Pharmacother; 2004 Oct; 5(10):2053-8. PubMed ID: 15461540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.
    Silver H
    Int Clin Psychopharmacol; 2003 Nov; 18(6):305-13. PubMed ID: 14571150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.
    Brennan JA; Graf R; Grauer SM; Navarra RL; Pulicicchio CM; Hughes ZA; Lin Q; Wantuch C; Rosenzweig-Lipson S; Pruthi F; Lai M; Smith D; Goutier W; van de Neut M; Robichaud AJ; Rotella D; Feenstra RW; Kruse C; Broqua P; Beyer CE; McCreary AC; Pausch MH; Marquis KL
    J Pharmacol Exp Ther; 2010 Jan; 332(1):190-201. PubMed ID: 19828876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia.
    Terevnikov V; Joffe G; Stenberg JH
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25991654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.
    Dold M; Aigner M; Lanzenberger R; Kasper S
    Int J Neuropsychopharmacol; 2015 May; 18(9):. PubMed ID: 25939614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha7 nicotinic acetylcholine receptor agonists and PAMs as adjunctive treatment in schizophrenia. An experimental study.
    Marcus MM; Björkholm C; Malmerfelt A; Möller A; Påhlsson N; Konradsson-Geuken Å; Feltmann K; Jardemark K; Schilström B; Svensson TH
    Eur Neuropsychopharmacol; 2016 Sep; 26(9):1401-1411. PubMed ID: 27474687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat.
    Björkholm C; Frånberg O; Malmerfelt A; Marcus MM; Konradsson-Geuken Å; Schilström B; Jardemark K; Svensson TH
    Int J Neuropsychopharmacol; 2014 Oct; 18(3):. PubMed ID: 25522408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders.
    Mendonça Júnior FJ; Scotti L; Ishiki H; Botelho SP; Da Silva MS; Scotti MT
    Mini Rev Med Chem; 2015; 15(8):630-47. PubMed ID: 25694077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvoxamine as an adjunctive agent in schizophrenia.
    Silver H
    CNS Drug Rev; 2001; 7(3):283-304. PubMed ID: 11607044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.